Prescient Therapeutics Investor Briefing – 27 May
Prescient Therapeutics (ASX: PTX) Webcast Replay
Prescient Therapeutics (ASX:PTX) is focused on developing novel, personalised therapies against a range of cancers.
As a part of our ‘Meet the CEOs’ series, CEO Steven Yatomi-Clarke provides valuable insights to the company, its key markets and industry, and future prospects.
Recorded on 27th May 2020 at 12pm (AEST).
Join the next Meet the CEOs webcastFEATURE SPEAKERS
Steven Yatomi-Clarke
CEO & Managing Director
Prescient Therapeutics (ASX:PTX) is focused on developing novel, personalised therapies against a range of cancers. Prescient’s universal CAR-T and targeted therapies are both personalised medicine approaches that seek to improve patient outcomes and provide new tools for clinicians in combating cancer.
